EUVIMEDEUVIMED entdecken
Crossref

Efficient gram-scale synthesis and preclinical evaluation of an escin-derived therapeutic for ovarian cancer

Chin Leong Wong, Tiffany Yuen Kwan Au, Chi-Shing Chan

Bioorganic & Medicinal Chemistry · 2026-08 · 139 · 118705

DOI: 10.1016/j.bmc.2026.118705 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bioorganic & Medicinal Chemistry, 2026-08. Verfasst von Chin Leong Wong und 2 weiteren Autor:innen. Beteiligte Einrichtung: Evaeon (HK) Life Technology Limited, Hong Kong. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Antineoplastic Agents, Escin. Die Arbeit nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Ovarian cancer is the most lethal gynecologic malignancy, characterized by a poor five-year survival rate for patients with advanced-stage disease. EV-S008, an escin derivative, exhibits potent anti-ovarian cancer activity; however, its preclinical development has been hindered by inefficient synthetic methodologies. In this study, we report a rational, seven-step synthetic route for EV-S008 that achieves a 40-fold increase in yield and produces material with 99.3% purity on a gram scale. EV-S008 demonstrated broad cytotoxicity across multiple human ovarian cancer cell lines, with IC50 values ranging from 1.2 to 11 μM. Pharmacokinetic analyses revealed that intraperitoneal (IP) administration achieved favorable bioavailability and sustained plasma drug level (prolonged T1/2) compared to oral dosing, and produced remarkably high concentrations in both ovary (28,810 ng/g) and peritoneal fluid (922,500 ng/mL), both notably exceeding in vitro IC50 values. In an ES-2-Luc xenograft nude mouse model, dose-dependent efficacy was observed, with IP administration of 10 mg/kg EV-S008 achieving 78% tumor growth inhibition (TGI) and significantly prolonged survival (p = 0.005). Altogether, these findings establish EV-S008 as a promising therapeutic candidate for ovarian cancer treatment via intraperitoneal delivery.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsAntineoplastic AgentsEscinFemaleHumansAnimalsCell Line, TumorMiceMice, NudeDrug Screening Assays, AntitumorCell ProliferationDose-Response Relationship, DrugStructure-Activity RelationshipXenograft Model Antitumor Assays

Stichwörter der Autor:innen

Escin derivativeGram-scale synthesisIntraperitoneal drug deliveryOvarian cancerPentacyclic triterpenoidPeritoneal metastasesXenograft mouse model

Substanzen

Antineoplastic AgentsEscin

Autor:innen und Institutionen

  • Evaeon (HK) Life Technology Limited, Hong Kong.
  • Evaeon (HK) Life Technology Limited, Hong Kong. Electronic address: chishingchan@evaeon.com.

Zitieren

APA

Wong, C. L., Au, T. Y. K., & Chan, C. S. (2026). Efficient gram-scale synthesis and preclinical evaluation of an escin-derived therapeutic for ovarian cancer. Bioorganic & Medicinal Chemistry, 139, 118705. https://doi.org/10.1016/j.bmc.2026.118705

Vancouver

Wong CL, Au TYK, Chan CS. Efficient gram-scale synthesis and preclinical evaluation of an escin-derived therapeutic for ovarian cancer. Bioorganic & Medicinal Chemistry. 2026;139:118705. doi:10.1016/j.bmc.2026.118705

BibTeX
@article{Wong2026,
  author = {Wong, Chin Leong and Au, Tiffany Yuen Kwan and Chan, Chi-Shing},
  title = {Efficient gram-scale synthesis and preclinical evaluation of an escin-derived therapeutic for ovarian cancer},
  journal = {Bioorganic & Medicinal Chemistry},
  year = {2026},
  volume = {139},
  pages = {118705},
  doi = {10.1016/j.bmc.2026.118705}
}
Kostenlos starten →